** Shares of BioRestorative Therapies rise 15.2% to $1.52 premarket
** Co says the U.S. FDA has cleared an amendment to the protocol of its ongoing mid-stage study on cell therapy candidate BRTX-100 for chronic lumbar disc disease (cLDD)
** Protocol amendment replaces saline injection in the placebo group with a sham injection - BRTX
** Co says the amendment removes the possibility of transient clinical outcomes in the placebo group
** "This positive change in our protocol will not have any impact from a timing perspective, affirming our already established 2024 enrollment completion target” - BRTX
** Up to last close, stock down 24% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Comments